Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 3, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital (as of Dec 30, 2016): 5,368,316,062 ordinary shares of 25 pence each.
- Treasury Shares: 458,205,950 ordinary shares.
- Total Voting Rights: 4,910,110,112.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data or discussion of changes in share capital or voting rights is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share counts intended to assist shareholders in calculating notification thresholds under Financial Conduct Authority rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,910,110,112) against the latest annual report to confirm the denominator for disclosure threshold calculations.
- Confirm the number of shares held in Treasury (458,205,950) to ensure accurate calculation of free float.
- Review the Company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains no financial metrics.